血管内皮生长因子在非小细胞肺癌组织中的表达及其临床意义  

Expression and clinical significance of VEGF in NSCLC

作　　者：袁五营[1] 李遂莹[1] 李建军[1] 高夏[1] 王济森 聂志鸿 李大军 乔保安 

机构地区：[1]河南省胸科医院胸外科,河南450003 [2]河南省济源市第一人民医院胸外科,河南济源454600

出　　处：《中国现代医学杂志》2005年第24期3743-3745,共3页China Journal of Modern Medicine

基　　金：河南科技攻关计划项目(No:0424410019)

摘　　要：目的探讨血管内皮生长因子(vascular endothelial growth factor,VEGF)在NSCLC中表达及其临床病理特征之间的关系。方法应用免疫组织化学技术检测100例NSCLC和60例肺良性病变组织中VEGF的表达。结果VEGF在NSCLC中的表达率高于肺良性病变组(P<0.01),并且与患者的年龄、性别、肿瘤的大小、分化程度以及组织类型之间比较差异无显著性(P>0.05)。而在有淋巴结转移组和III期+IV期组的表达分别显著高于无淋巴结转移组和I期+II期组(P<0.05)。结论VEGF表达与NSCLC的病程分期和淋巴结转移密切相关,可作为评估NSCLC病程、转移潜力和判断预后的一个重要标志物。[Objective] Probe into VEGF relation among expression in NSCLC and the clinical pathological characteristic. [Methods] Use immunohistochemical technique to measure expression of VEGF in 100 NSCLC and 60 lung benign tissue. [Results] The expression rate in NSCLC of VEGFF is higher than the lung benign tissue group （P 〈0.01）, and has no statistical difference with age, sex, size, degree of differention, pathological type （P 〉 0.05）. Relative expression in group with lymph node metastasis and StageⅢ, Stage ＋Ⅳ group is statistically higher than group with no lymph node metastasis and Stage Ⅰ, Stage Ⅱ （P 〈0.05）. [Conclusions] VEGF expression and NSCLC stage are closely related to metastasis of lymph node, can seen as an important clinical biochemical factor.

关 键 词：非小细胞肺癌 血管内皮生长因子 免疫组织化学 

分 类 号：R734.2[医药卫生—肿瘤]